Q-Line Biotech Limited
NNSE:QLINE569.00
INR
-3.45
(-0.60%)
Q-Line Biotech Limited
NSE:QLINE
(National Stock Exchange of India)
Recent
price
569.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Q-Line Biotech Limited is an India-based medical technology and in-vitro diagnostics (IVD) company engaged in the manufacturing, marketing, and distribution of diagnostic analyzers, reagents, and laboratory consumables. Founded in 2014 and headquartered in Lucknow, Uttar Pradesh, India, the company operates across the healthcare diagnostics sector, serving clinical laboratories, hospitals, blood banks, diagnostic chains, research institutions, and healthcare providers across India and international markets in Asia, Africa, and the Middle East. Q-Line Biotech classifies its operations and product offerings into several core segments: Clinical Chemistry, which provides semi-automated and fully automated biochemistry analyzers, liquid-stable clinical chemistry reagents, specific protein assays, and diagnostic calibrators and controls; Hematology, comprising 3-part and 5-part differential automated hematology cell counters, diluents, lysing solutions, and system cleaning reagents; Immunoassay and Point-of-Care Testing (POCT), featuring rapid diagnostic test cassettes for infectious diseases including dengue, malaria, hepatitis, and HIV, fluorescence immunoassay (FIA) analyzers, cardiac marker test kits, and hormone estimation assays; Molecular Diagnostics, which includes real-time polymerase chain reaction (RT-PCR) test kits, automated nucleic acid extraction systems, and viral transport media; Critical Care Diagnostics, offering automated electrolyte analyzers, blood gas systems, and associated consumable cartridges; and Laboratory Consumables and Equipment, supplying vacuum blood collection tubes, micropipettes, centrifuge devices, and plastic laboratory disposables. In recent developments, Q-Line Biotech completed its initial public offering (IPO) and listed its equity shares on the National Stock Exchange of India (NSE: QLINE) to support capital expenditure and operational scale. The company has expanded its domestic manufacturing capacity under the Make in India initiative, operationalized automated production lines for diagnostic reagents and lateral flow rapid cards, rolled out high-throughput automated chemiluminescence immunoassay (CLIA) platforms, and entered strategic supply partnerships with regional healthcare networks and government health agencies.